These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 9788616

  • 1. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z.
    Cancer Res; 1998 Oct 15; 58(20):4640-5. PubMed ID: 9788616
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
    Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H.
    Cancer Res; 1994 Oct 15; 54(20):5474-8. PubMed ID: 7522959
    [Abstract] [Full Text] [Related]

  • 3. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 15; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 4. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA.
    Prostate; 2008 Jul 01; 68(10):1133-42. PubMed ID: 18454446
    [Abstract] [Full Text] [Related]

  • 5. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S, Lee TJ, Wang R, Culig Z, Delorme N, Caffey S, Marrero L, Aguirre J.
    Prostate; 2007 Feb 01; 67(2):178-89. PubMed ID: 17044040
    [Abstract] [Full Text] [Related]

  • 6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 7. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF, Wang Y, Cho JY, Libermann TA.
    Cancer Res; 2003 May 01; 63(9):2206-15. PubMed ID: 12727841
    [Abstract] [Full Text] [Related]

  • 8. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD, Gleave ME.
    Cancer Res; 2000 Oct 15; 60(20):5825-31. PubMed ID: 11059779
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 15; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-4 in patients with prostate cancer.
    Takeshi U, Sadar MD, Suzuki H, Akakura K, Sakamoto S, Shimbo M, Suyama T, Imamoto T, Komiya A, Yukio N, Ichikawa T.
    Anticancer Res; 2005 Jun 15; 25(6C):4595-8. PubMed ID: 16334148
    [Abstract] [Full Text] [Related]

  • 11. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells.
    Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M, Lin MF, Tu Y.
    Oncogene; 2006 Jun 22; 25(26):3719-34. PubMed ID: 16449965
    [Abstract] [Full Text] [Related]

  • 12. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
    Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ.
    Cancer Res; 2005 Jul 01; 65(13):5965-73. PubMed ID: 15994976
    [Abstract] [Full Text] [Related]

  • 13. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep 01; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 14. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ, Robson CN, Neal DE, Leung HY.
    Oncogene; 2002 Aug 01; 21(33):5069-80. PubMed ID: 12140757
    [Abstract] [Full Text] [Related]

  • 15. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R.
    Oncogene; 2006 Mar 30; 25(14):2011-21. PubMed ID: 16434977
    [Abstract] [Full Text] [Related]

  • 16. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A, Fraizer GC, Piantanelli L, Saunders GF.
    Anticancer Res; 2001 Mar 30; 21(1A):1-10. PubMed ID: 11299720
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 18. Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer.
    Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP.
    Cancer Res; 2000 Oct 01; 60(19):5494-8. PubMed ID: 11034093
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.